Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 50 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
491 17.8 months Castration-resistant prostate cancer 5 Chemotherapy
Memorial Sloan-Kettering Cancer Center United States 6/2011
Treatment Details: Patients: This phase III study involved men with castration-resistant prostate cancer. Patients were divided into two treatment groups. Group A consisted of 476 patients with a median age
 
492 17.8 months Metastatic breast cancer 3 Biologic therapy
Chemotherapy
Regina Elena National Cancer Institute Italy 9/2008
Treatment Details: Patients: This phase II study involved 42 women with previously treated metastatic breast cancer. The median age was 57, ranging from 33 to 82 years old. Treatment: Patients were treat
 
493 17.8 months Recurrent ovarian cancer 4 Chemotherapy
Charité University Medical Center Germany 7/2008
Treatment Details: Patients: This phase III study involved 502 women with recurrent ovarian cancer. Of these, 208 women had platinum-resistant cancer. Their average age was 60.5 years, ranging from 28 to 84
 
494 17.8 months Androgen-independent prostate cancer 4 Biologic therapy
Chemotherapy
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center United States 4/2008
Treatment Details: Patients: This phase II study involved 70 men with androgen-independent prostate cancer. They ranged in age from 52 to 85 years. Treatment: Patients were treated with the chemotherapy
 
495 17.8 months Malignant Pleural Mesothelioma 5 Biologic therapy
Chemotherapy
Medical University of Lubeck Germany 3/2003
Treatment Details: Patients: This Phase II study involved 27 patients with advanced malignant pleural mesothelioma. Treatment: The treatment consisted of a combination of hyperthermia with three chemother
 
496 17.8 months Metastatic, castration-resistant prostate cancer 4 Chemotherapy
Hormone
Texas Oncology and US Oncology Research United States 11/2011
Treatment Details: Patients: This phase II study involved men with metastatic castration-resistant prostate cancer who were separated into two separate treatment groups. Group A had 110 patients with a media
 
497 17.8 months Advanced castration-resistant prostate cancer 5 Biologic therapy
Chemotherapy
University of Southern California Norris Comprehensive Cancer Center United States 8/2013
Treatment Details: Patients: This phase 3 study involved advanced castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A had 496 patients with a median age
 
498 17.7 months Metastatic, Castration-Resistant Prostate Cancer 5 Chemotherapy
Hormone
Yale Cancer Center United States 4/2015
Treatment Details: Patients: This phase 3 study involved 533 metastatic castration-resistant prostate cancer patients who had not received prior chemotherapy. The median patient age was 70 years. Treatmen
 
499 17.7 months Stage III NSCLC 4 Chemotherapy
University of Chicago Medical Center United States 10/2002
Treatment Details: Patients: This Phase II study involved a total of 175 patients with stage III non-small cell lung cancer. Patients were divided into three groups. Group A contained 62 patients. Group B c
 
500 17.7 months Melanoma 4 Alternative
Biologic therapy
Moffitt Cancer Center United States 9/2009
Treatment Details: Patients: This phase 2 study involved patients with advanced melanoma. Patients were divided into two separate treatments groups. Group A consisted of 58 patients with a median age of 58
 
Page 50 of 187  | Previous Page  | Next Page